Comparing Harvard Bioscience (HBIO) and Its Competitors
Harvard Bioscience (NASDAQ: HBIO) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Harvard Bioscience to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
Institutional and Insider Ownership
60.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 9.8% of Harvard Bioscience shares are owned by company insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Harvard Bioscience and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Harvard Bioscience||$100.79 million||$3.21 million||-36.11|
|Harvard Bioscience Competitors||$2.06 billion||$438.96 million||-77.91|
Harvard Bioscience’s competitors have higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Harvard Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Harvard Bioscience’s competitors have a beta of 0.89, meaning that their average stock price is 11% less volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Harvard Bioscience and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Harvard Bioscience Competitors||266||1844||3300||105||2.59|
Harvard Bioscience currently has a consensus target price of $5.75, suggesting a potential upside of 76.92%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.73%. Given Harvard Bioscience’s stronger consensus rating and higher possible upside, research analysts clearly believe Harvard Bioscience is more favorable than its competitors.
This table compares Harvard Bioscience and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Harvard Bioscience Competitors||-328.03%||-35.97%||-12.59%|
Harvard Bioscience beats its competitors on 9 of the 13 factors compared.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.